Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Virios Therapeutics Inc (VIRI)

Virios Therapeutics Inc (VIRI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,416
  • Shares Outstanding, K 8,330
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,960 K
  • 60-Month Beta 1.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.26
Trade VIRI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.74
  • Most Recent Earnings -0.28 on 11/14/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 787.59% ( +4.44%)
  • Historical Volatility 63.65%
  • IV Percentile 99%
  • IV Rank 88.29%
  • IV High 891.41% on 10/19/22
  • IV Low 4.75% on 12/10/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 1.24
  • Today's Open Interest 7,329
  • Open Int (30-Day) 7,601

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.16
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +70.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2579 +12.45%
on 10/31/22
0.3978 -27.10%
on 11/11/22
+0.0150 (+5.45%)
since 10/28/22
3-Month
0.2579 +12.45%
on 10/31/22
8.8300 -96.72%
on 09/16/22
-6.9067 (-95.97%)
since 08/30/22
52-Week
0.2579 +12.45%
on 10/31/22
9.1109 -96.82%
on 08/15/22
-4.6600 (-94.14%)
since 11/26/21

Most Recent Stories

More News
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.2800 (-3.45%)
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases...

VIRI : 0.2800 (-3.45%)
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.2800 (-3.45%)
Virios Therapeutics, Inc. Announces Closing of Public Offering

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.2800 (-3.45%)
Pre-Market Brief: Stocks Mixed Ahead Of FOMC Meeting

December S&P 500 futures (ESZ22) are moderately down -0.08% this morning after three major US benchmark indices rebounded from 9-week lows to close higher during the regular session as market participants...

ESZ22 : 4,100.75 (+0.48%)
F : 13.93 (+0.22%)
GM : 40.73 (+0.42%)
VIRI : 0.2800 (-3.45%)
ENVX : 13.07 (+0.15%)
CGNX : 49.78 (+4.25%)
CHNG : 27.49 (+0.26%)
UNH : 547.87 (+0.02%)
Virios Therapeutics, Inc. Announces Pricing of Public Offering

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.2800 (-3.45%)
Virios Therapeutics, Inc. Announces Proposed Public Offering

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.2800 (-3.45%)
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.2800 (-3.45%)
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.2800 (-3.45%)
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia...

VIRI : 0.2800 (-3.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Virios Therapeutics Inc. is a biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Virios Therapeutics Inc. is based in Alpharetta, Georgia.

See More

Key Turning Points

3rd Resistance Point 0.3203
2nd Resistance Point 0.3127
1st Resistance Point 0.3013
Last Price 0.2800
1st Support Level 0.2823
2nd Support Level 0.2747
3rd Support Level 0.2633

See More

52-Week High 9.1109
Fibonacci 61.8% 5.7291
Fibonacci 50% 4.6844
Fibonacci 38.2% 3.6397
Last Price 0.2800
52-Week Low 0.2579

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar